Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan 30;94(2):227-30.
doi: 10.1038/sj.bjc.6602922.

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

A M Al Murri  1 , J M S Bartlett, P A Canney, J C Doughty, C Wilson, D C McMillan
Affiliations

Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

A M Al Murri et al. Br J Cancer. .

Abstract

Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer. The GPS was constructed as follows: patients with both an elevated C-reactive protein (>10 mg l(-1)) and hypoalbuminaemia (<35 g l(-1)) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively. In total, 96 patients were studied. During follow-up 51 patients died of their cancer. On multivariate analysis of the GPS and treatment received, only the GPS (HR 2.26, 95% CI 1.45-3.52, P<0.001) remained significantly associated with cancer-specific survival. The presence of a systemic inflammatory response (the GPS) appears to be a useful indicator of poor outcome independent of treatment in patients with metastatic breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The relationship between an inflammation-based prognostic score (GPS, 0, 1, 2 from top to bottom) and survival in patients with metastatic breast cancer.
See this image and copyright information in PMC

References

    1. Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, Blamey RW, Robertson JF (1995) Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 21: 504–509 - PubMed
    1. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634–1639 - PMC - PubMed
    1. Ali SM, Harvey HA, Lipton A (2003) Medical management of bone metastases; metastatic breast cancer. overview of treatment. Clin Orthop Relat Res 415: S132–S137 - PubMed
    1. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9: 617–632 - PubMed
    1. Christakis NA, Lamont EB (2000) Extent and determinants of error in doctors'prognoses in terminally ill patients: prospective cohort study. Br Med J 320: 469–472 - PMC - PubMed